|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
Thrombotargets is developing new drug for hemostasis, atherosclerosis, aging and thrombosis. Know the revolutionary antihemorrhagic agents for all kind of bleeding treatments.
Novel and significantly radical approach for the treatment of bleeding disorders, using a topical formulation. See all antihemorrhagic information of new discover TT-103MH for bleeding disorders.
Know the TT-103MH haemostatic agent for all kind of bleeding treatments discovered by Thrombotargets, the biotech corporation that works to improve the quality of life for millions of people.
Thrombotargets is developing new drug for hemostasis, atherosclerosis, aging and thrombosis. Know the revolutionary antihemorrhagic agents for all kind of bleeding treatments.
|
|
|
|
